H.I.G. Capital acquires Canadian biopharma company

The $34 billion private equity powerhouse H.I.G. Capital announced the acquisition of BioVectra in a bid to further expand the Canadian company’s biopharmaceutical business. The BioVectra leadership team has expanded its presence by expanding capacity with the support of in recent years. BioVectra CEO Oliver Technow outlined the company’s growth trajectory that will be supported …